한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제27권2호
  • /
  • Pages.92-98
  • /
  • 2017
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

Colistimethate 분무요법 시행 환자에서 투여 전후 신기능의 변화

Changes in Renal Function by Nebulized Colistimethate Treatment

  • Ahn, Hye Jin (Department of Pharmacy, Yonsei University Health System) ;
  • Jung, Yoo Jin (Department of Pharmacy, Yonsei University Health System) ;
  • Kim, Jae Song (Department of Pharmacy, Yonsei University Health System) ;
  • Kim, Soo Hyun (Department of Pharmacy, Yonsei University Health System) ;
  • Son, Eun Sun (Department of Pharmacy, Yonsei University Health System)
  • 투고 : 2017.03.06
  • 심사 : 2017.06.16
  • 발행 : 2017.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Nebulized colistimethate is increasingly used, because there are problems such as renal dysfunction and low distribution within the lungs when colistimethate is administered intravenously. This study was designed to compare and analyze the changes in renal function by of nebulized colistimethate treatment for its safe administration. Methods: This study retrospectively reviewed the electronic medical records of adult patients above 19 years old, receiving only the nebulized colistimethate at least 4 days in Yonsei university health system from Nov 2014 to Aug 2015. Acute kidney injury (AKI) was determined by using the RIFLE criteria (Risk, Injury, Failure, Loss and End-stage renal disease) according to serum creatinine (SCr) levels before and after use of nebulized colistimethate. Results: 48 patients were included our study and their SCr increased significantly after nebulized colistimethate treatment ($SCr_0$ vs. $SCr_1$; $0.85{\pm}0.80$ vs. $1.00{\pm}0.82mg/dL$, n=48, p<0.001), but the changes were in normal range according to the standards at Yonsei university health $system^a$. Among 48 patients, 38 patients were in the non-AKI group (79.2%), and 10 patients developed AKI (20.8%). Within the AKI group, 2 patients were in the Injury group (20%) and the other 8 in the Risk group (80%). Conclusion: There was no significant difference in age, dosage and duration of treatment between AKI group and non-AKI group (p>0.05). The study has a significance in that it reviewed the safety of nebulized colistimethate only treatment to national patients, analyzing its nephrotoxicity. It has confirmed that nebulized colistimethate is a safer method than intravenous injection, and requires to establish a guideline for the use of nebulized colistimethate in further studies with broader patient groups. $^a$ : SCr Male 0.68-1.19 mg/dL, Female 0.49-0.91 mg/dL.

키워드

참고문헌

  1. 대한감염학회: 항생제의 길잡이 제3판 p352.
  2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. The Lancet Inf Dis. 2006;6(9):589-601. https://doi.org/10.1016/S1473-3099(06)70580-1
  3. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979;18(20):4425-30. https://doi.org/10.1021/bi00587a024
  4. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Austral 1970;2(20):923-24.
  5. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit care 2006;10(1):1.
  6. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7(5):1.
  7. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negativebacterial infections. Clin Inf Dis 2005;40(9):1333-41. https://doi.org/10.1086/429323
  8. Levin AS. Treatment of Acinetobacter spp. infections. Exp opin Pharmaco 2003;4(8):1289-96. https://doi.org/10.1517/14656566.4.8.1289
  9. Martinez-Garcia MA. Nebulized Antibiotic Therapy. Archivos de Bronconeumologia (English Edition) 2014;50(10):415-6. https://doi.org/10.1016/j.arbr.2014.03.018
  10. Sabuda DM, Laupland K, Pitout J, et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Cana J Inf Dis Med Microbio 2008;19(6):413-8.
  11. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Int Med J 2007;37(7):495-8. https://doi.org/10.1111/j.1445-5994.2007.01404.x
  12. Lu Q, Girardi C, Zhang M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Int Care Med 2010;36(7):1147-55. https://doi.org/10.1007/s00134-010-1879-4
  13. Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. J Am Soc Anesth 2012;117(6):1335-47.
  14. Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Inf Dis 2005;41(5): 754-7. https://doi.org/10.1086/432583
  15. Naesens R, Vlieghe E, Verbrugghe W, et al. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Inf Dise 2011;11(1):317. https://doi.org/10.1186/1471-2334-11-317
  16. Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. CHEST J 2013;144(6):1768-75. https://doi.org/10.1378/chest.13-1018
  17. Insert paper: SamChunDang Pharm. Co., Ltd.
  18. Kim DK, Joo KW, Acute Kidney Injury: Clinical Praetice Guidelinelines. Korean J Med 2015; 88(4):357-62. https://doi.org/10.3904/kjm.2015.88.4.357
  19. Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Inf Dis 2013;57(9):1300-03. https://doi.org/10.1093/cid/cit453
  20. DeRyke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Chemoth 2010;54(10):4503-05. https://doi.org/10.1128/AAC.01707-09
  21. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacoth 2004; 38(9):1449-59. https://doi.org/10.1345/aph.1D592
  22. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents.New Engl J Med 1977;296(13):722-8. https://doi.org/10.1056/NEJM197703312961305
  23. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicro Chemoth 1993;32(2):325-4. https://doi.org/10.1093/jac/32.2.325
  24. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. Med Toxicol Adve Drug Expe 1988;3(5):376-386.
  25. Deray G. Amphotericin B nephrotoxicity. J Antimicro Chemoth 2002;49(suppl1):37-41 https://doi.org/10.1093/jac/49.suppl_1.37
  26. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health-syst Pharm 2005;62(1):39-47.
  27. Park, S. Y., et al. Clinical Effectiveness and Nephrotoxicity of Aerosolized Colistin Treatment in Multidrug-Resistant Gram-Negative Pneumonia. Korean J Critical Care Med 2016, 31.3: 208-220. https://doi.org/10.4266/kjccm.2016.00129
  28. Cho, A Young et al. Comparison of Clinical Characteristics of Patients with Acute Kidney Injury after Intravenous versus Inhaled Colistin Therapy. Kidney Research and Clinical Practice 35.4 (2016):229-232. PMC. Web. 21 Apr. 2017. https://doi.org/10.1016/j.krcp.2016.07.005